Using radiation to treat early-stage prostate cancer with limited metastases
Phase 2 randomized Total Eradication of metastatic lesions following definitive Radiation to the Prostate in de novo oligometaStatic prostate cancer (TERPS) trial
This study is looking at how well high-dose radiation treatment works for people with newly diagnosed oligometastatic prostate cancer, where the cancer has spread but is still limited, to see if it can help stop the cancer from spreading further and possibly even cure it.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Maryland Baltimore NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project ID | NIH-10910077 on NIH RePORTER |
What this research studies
This research investigates the effectiveness of total radiation treatment for patients with newly diagnosed oligometastatic prostate cancer, where cancer has spread but is limited in number and location. The approach involves delivering high-dose, focused radiation to all tumor deposits to prevent further spread of the disease. By utilizing advanced genomic profiling, the study aims to understand how radiation affects the immune response and the overall metastatic process. This trial represents a novel opportunity to explore whether consolidative radiation can provide a curative treatment for these patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are men diagnosed with de novo oligometastatic prostate cancer who have limited metastatic lesions.
Not a fit: Patients with advanced metastatic prostate cancer or those who do not have oligometastatic disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new treatment paradigm that significantly improves outcomes for patients with oligometastatic prostate cancer.
How similar studies have performed: Previous studies have shown promising results with focused radiation in recurrent oligometastatic prostate cancer, suggesting potential success for this novel approach.
Where this research is happening
Baltimore, United States
- University of Maryland Baltimore — Baltimore, United States (Active)
Researchers
- Principal investigator: Tran, Phuoc T. — University of Maryland Baltimore
- Study coordinator: Tran, Phuoc T.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.